Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis

¹ Columbia University, United States
² McGill University Health Centre, Canada
³ Massachusetts General Hospital, United States
⁴ Massey University, New Zealand

^* To whom correspondence should be addressed. E-mail: rgb9{at}columbia.edu.

Accepted 16 June 2006

	Abstract

Objective: To evaluate the efficacy of tiotropium, a long-acting anticholinergic therapy, on clinical events, symptom scales, pulmonary function and adverse events in stable chronic obstructive pulmonary disease (COPD).

Data sources: A compilation of systematic searches of the Cochrane Trials database, MEDLINE, EMBASE, CINAHL and hand-search of 20 respiratory journals. Missing data were obtained from authors and the manufacturer.

Design: A systematic review of high quality randomised controlled trials.

Review methods: Randomised trials of 12 week's duration comparing tiotropium to placebo, ipratropium bromide, or long-acting 2-agonists (LABA). Studies were pooled to yield odds ratios (OR) or weighted mean differences with 95% confidence intervals (CI).

Results: Nine trials (8,002 patients) met inclusion criteria. Tiotropium reduced the odds of a COPD exacerbation (OR 0.73; 95% CI, 0.66 to 0.81) and related hospitalisation (OR 0.68; 95% CI, 0.54 to 0.84) but not pulmonary (OR 0.50; 95% CI, 0.19 to 1.29) or all-cause (OR 0.96; 95% CI, 0.63 to 1.47) mortality compared to placebo and ipratropium. Reductions in exacerbations and hospitalisations compared to LABA were not statistically significant. Similar patterns were evident for quality-of-life and symptom scales. Tiotropium yielded greater increases in FEV1 and FVC from baseline to 6-12 months than did placebo, ipratropium and LABA. Decline in FEV1 over one year was 30 ml (95% CI, 7 to 53 ml) slower with tiotropium than with placebo and ipratropium (data were not available for LABA). Reports of dry mouth and urinary tract infections were increased with tiotropium.

Conclusions: Tiotropium reduced COPD exacerbations and related hospitalisations. In addition, tiotropium improved quality-of-life and symptoms, and may have slowed decline in FEV1. Long-term trials are warranted to evaluate the effects of tiotropium on decline in FEV1 and to clarify its role compared to LABA.

Keywords: bronchodilator agents, cholinergic antagonists, chronic bronchitis, chronic obstructive pulmonary disease, emphysema

This article has been cited by other articles:

				S. Singh, Y. K. Loke, and C. D. Furberg Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis JAMA, September 24, 2008; 300(12): 1439 - 1450. [Abstract] [Full Text] [PDF]

				Y. Oba Does Tiotropium Reduce Hospitalizations in Chronic Obstructive Pulmonary Disease? Ann Intern Med, April 15, 2008; 148(8): 626 - 626. [Full Text] [PDF]

				K. Lin, B. Watkins, T. Johnson, J. A. Rodriguez, and M. B. Barton Screening for Chronic Obstructive Pulmonary Disease Using Spirometry: Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, April 1, 2008; 148(7): 535 - 543. [Abstract] [Full Text] [PDF]

				M Sridhar, R Taylor, S Dawson, N J Roberts, and M R Partridge A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease Thorax, March 1, 2008; 63(3): 194 - 200. [Abstract] [Full Text] [PDF]

				J. A. Wedzicha, P. M. A. Calverley, T. A. Seemungal, G. Hagan, Z. Ansari, R. A. Stockley, and for the INSPIRE Investigators The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 19 - 26. [Abstract] [Full Text] [PDF]

				T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline Ann Intern Med, November 6, 2007; 147(9): 639 - 653. [Abstract] [Full Text] [PDF]

				J. Bourbeau, G. Ford, H. Zackon, N. Pinsky, J. Lee, and G. Ruberto Impact on patients' health status following early identification of a COPD exacerbation Eur. Respir. J., November 1, 2007; 30(5): 907 - 913. [Abstract] [Full Text] [PDF]

				N. A. Hanania and J. F. Donohue Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators Proceedings of the ATS, October 1, 2007; 4(7): 526 - 534. [Abstract] [Full Text] [PDF]

				J. B. Soriano and N. C. Barnes Eppur si muove, or COPD treatment success and inflammation Eur. Respir. J., September 1, 2007; 30(3): 409 - 410. [Full Text] [PDF]

				J. Chang and Z. Mosenifar Differentiating COPD From Asthma in Clinical Practice J Intensive Care Med, September 1, 2007; 22(5): 300 - 309. [Abstract] [PDF]

				K. M. Beeh, E. Derom, F. Kanniess, R. Cameron, M. Higgins, and A. van As Indacaterol, a novel inhaled {beta}2-agonist, provides sustained 24-h bronchodilation in asthma Eur. Respir. J., May 1, 2007; 29(5): 871 - 878. [Abstract] [Full Text] [PDF]

				S. Shafazand Review: long acting {beta}2 adrenoceptor agonists are effective in poorly reversible chronic obstructive pulmonary disease Evid. Based Med., February 1, 2007; 12(1): 12 - 12. [Full Text] [PDF]

				S. Shafazand Review: anticholinergics but not {beta}2 agonists reduce exacerbations requiring hospital admission and respiratory deaths in COPD Evid. Based Med., February 1, 2007; 12(1): 13 - 13. [Full Text] [PDF]